Review
Copyright ©2014 Baishideng Publishing Group Inc.
World J Pharmacol. Dec 9, 2014; 3(4): 97-109
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.97
Table 1 Patents concerning the inhibition of bacterial adhesion and colonization
Patent titleDescriptionApplicationdateInventorsPublicationnumber
Capsular polysaccharide adhesion antigen preparation, purification and useGeneral method for preparing pure capsular exopolysaccharide adhesins strains of adhesin coagulase-negative staphylococci to produce vaccines1994Pier Gerald BUS5980910 (A)
Method for inhibiting microbial adhesion on surfacesA method for inhibiting microbial adhesion on surfaces in contact with an aqueous system is disclosed and involves adding a treatment comprising an alkyl sulfosuccinate surfactant to the system1995Wright J Barry; Michalopoulos Daniel LUS5512186
Method and apparatus for preventing adhesion and colonization of bacteria in medical devicesActivation of compounding photochemicals for preventing and eliminating adherence and colonization of bacteria1996Prescott Marvin AWO9806340 (A1)
Decorin binding protein compositions and methods of useDNA segments encoding these proteins and anti-(decorin binding protein) antibodies for use in the prevention of Borrelia colonization in an animal1996Guo Betty P; Hoeoek Magnus; Hanson MarkWO9727301 (A1)
Collagen binding protein compositions and methods of useDisclosed are the cna gene and cna-derived nucleic acid segments from Staphylococcus aur. Also disclosed are Col Binding Protein (CBP) for use in the treatment of pathological infections, and in particular, for use in the prevention of bacterial adhesion to Col1997Hoeek Magnus; Patti Joseph M; House-Pompeo Karen; Sthanam Narayana; Symersky JindrichUS6288214 (B1)
Surfactants for reducing bacterial adhesion onto surfacesInhibiting microbial colonization (ethylene oxide units) of a surface in contact with an aqueous system1997Donlan Rodney M; Elliot David L; Kapp Nancy J; Wiatr Christopher L; Rey PaulaUS6039965 (A)
Composition of treatment of CandidiasisInhibition of adhesion of Candida colonization by using probiotics (Lactobacillus reuteri, Bifidobacterium infantis, Bifidobacterium lactis, Lactobacillus acidophilus not viable and non-viable Lactobacillus casei)1998Dohnlek Margaret H; Wagner Robert Doug; Balish Edward; Hilty Milo DWO9917788 (A1)
Antimicrobial adhesion surfaceThe invention provides an implantable medical device with a hydrophilic coating to limit in vivo colonization of bacteria and fungi1999Zhong Samuel PUS6468649 (B1)
Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereofThe invention relates to novel compounds that mimic a chaperone G1 beta-strand or an amino terminal motif of a pilus subunit2000Hultgren Scott J; Sauer Frederic G; Waksman Gabriel; Fuetterer Klaus; Choudhury Devapriya; Knight Stefan D; Barnhart MichelleUS7041465 (B1)
C3 binding polypeptide of Streptococcus agalactiae group b-StreptococcusThe invention involves the identification of a human complement C3 binding polypeptide and the nucleic acid that encodes the polypeptide from Streptococcus agalactiae2000Smith Beverly L; Ferrieri PatriciaUS6582950 (B1)
Compounds directed against pilus biogenesis and activity in pathogenic bacteria, methods and compositions for synthesis thereofNovel fluorinated linker compounds and methods of synthesis are provided. Methods for using the fluorinated linker compounds in methods of solid-phase synthesis of the N-substituted amino acid compounds are also disclosed (inhibiting or preventing the formation of a pilus chaperone-subunit complex)2000Kilhlberg Jan; Larsson Andreas; Svensson Anette; Fex Tomas; Hultgren Scott J; Pinkner JerryWO2001020995
DbpA compositions and methods of useThe DBP gene and decorin protein compositions of Borrelia burgdorferi are disclosed The DBP protein and antigenic epitopes derived from them are contemplated for use in preventing bacterial adhesion to decorin2000Guo Betty P; Hook MagnusUS6312907
Composition and method for controlling microbial adhesion and biofilm formation of surfacesThe invention describes how coating of surfaces with an extract, particularly a fish extract, can significantly reduce microbial adhesion, attachment, colonization and biofilm formation on surfaces2003Gram Lone Kirsten; Vogel Birtefonnesbech; Bagge-Ravn DortheWO03092382 (A1)
Packaged antimicrobial medical device and method of preparing sameAn antimicrobial suture assembly (halogenated hydroxyl ethers, acyloxydiphenyl ethers, and combinations thereof) to substantially inhibit bacterial colonization2004Scalzo Howard; Fischer Jerome A; Rothenburger StephenUS2004220614 (A1)
Sealing materialA sealing material is presented (fluoropolymer layer, a reinforcing layer and an adhesive) to hinder growth and colonization of bacteria2004Patel Malay; Napolitano Michael; Hanrahan James R; Chu ChaokangUS2005250398 (A1)
Zn-releasing calcium phosphate (Zn-CaP) compounds for antimicrobial coating on orthodontic appliances and dental implantsCompositions of Zn-releasing calcium phosphate (Zn-CaP) compounds for use as anti-bacterial coatings for orthodontic brackets and dental implants2006Legeros Racquel Z; Legeros John P; Park Jae Hyun; Mijares DindoWO2007022211 (A2)
Composition for the administration of biologically active principles in gynaecological and rectal conditions and uses thereofThe invention relates to a composition for the administration of biologically active substances in gynaecological and rectal conditions, as well as the uses of said composition2007Strozzi Gianpaolo; Mogna LucaUS2010092440 (A1)
Enhanced treatments to kill or debilitate pathogenic microorganisms of a mammalian bodyThe novel treatments involve the use of anti-adhesive polysaccharide molecules to abolish or reduce the adhesion of Helicobacter pylori2008Nifantiev Nikolay; Wieland Gerhard DUS2011245198 (A1)
Non-leaching surface-active film compositions for microbial adhesion preventionCoating (surfactant) useful to prevent bacterial colonization on a variety of surface including surfaces of medical devices2008Gruening Rainer; Qu Xin; Merritt Karen; Chen Paul N; Falevich VitalyMX2008009326 (A)
Prevention and treatment of Gram-negative, flagellated bacterial infectionsEtpA which binds to the conserved region of the flagellin protein located at the tip of the flagella in Gram-negative bacteria (development vaccine)2008Fleckenstein James MUS2011206694 (A1)
Method for coating medical device1Method for coating a medical device to prevent bacterial adhesion, colonization and device-associated infection (isocyanate-terminated polymer)2010Stopek JoshuaJP2011019902 (A)
Novel Enterococcus faecium LJS-01 and its use as a probiotic1Enterococcus faecium LJS-01 shows good antimicrobial activity and strong capacity to adhere to intestinal epithelial cells2010Lin Chuen-FU; Wu Cheng-Nan; Lu Cheng-Hsiung; Hsu Wei-Li; Chiou Ming-TangTW201143631 (A)
Method for detecting colonization characteristic of lactobacillus in gastrointestinal tract on basis of green fluorescent protein1The invention relates to a method for detecting the colonization characteristic of lactobacillus in the gastrointestinal tract on the basis of green fluorescent protein2011Yanping Wang; Jingrui Wang; Jinju WangCN102604877 (A)
Prevention of bacterial adhesion1Prevention of adhesion of microorganisms on hard surfaces by the semi-permanent modification thereof during the cleaning process. A cleaning agent that contains surface-active polymers is used to prevent the bacterial colonization of hard surfaces2011Veith Birgit; Weide Mirko; Corbellini Francesca; Giesen Brigitte; Stumpe Stefan; Breves Roland; Barreleiro Paula; Karten Stefan; Bockmuehl Dirkl; Meier FrankWO2012010700 (A1)
Pyruvate-ferredoxin oxidoreductase (PFO) adhesive protein as a target for inhibiting the adherence of Trichomonas vaginalis and as a diagnosis and vaccinal target for trichomoniasis1Novel function of PFO upon participating in the cytoadherence of the Trichomonas vaginalis parasite to the hosting cell. The present invention enables development of vaccines for preventing the adhesion (and therefore the colonization) of parasites to the vaginal mucosa2011Verastegui Rossana ArroyoMX2011011361 (A)
Vacuum assisted percutaneous appliance1This device is stabilized by fibroblast in-growth and inhibits bacterial colonization2012Kantrowitz Allen B; Mortin Chris; Wadsworth JR Daniel CUS2013006186 (A1)
Table 2 Patents concerning the inhibition of bacterial secretion systems
Patent titleDescriptionApplicationdateInventorsPublicationnumber
Method for screening for inhibitors and activators of type III secretion machinery in Gram-negative bacteriaThis invention relates to mutant strains of Gram-negative bacteria that constitutively secrete proteins via the type III secretion machinery and to methods of identifying molecules that are able to activate or inhibit secretion in wild-type strains of Gram-negative bacteria2001Demers Brigitte; Sansonetti Philippe; Parsot ClaudeUS6696249 (B1)
Method of detecting substance inhibiting type III secretion mechanism of bacterium and the function of secretory protein thereofA method whereby a substance specifically inhibiting the type III secretion mechanism and the function of a type III secretory protein secreted therefrom can be detected in large amounts within a short period of time without depending on any animal infection experiments2001Omura Satoshi; Abe AkioKR1020020086208
Secreted Chlamydia polypeptides and method for identifying such polypeptides by their secretion by a type III secretion pathway of a Gram-negative bacteriaThe present invention uses a heterologous secretion system, namely a type III system, to investigate whether some Chlamydia proteins, especially Inc proteins and other proteins exhibiting a similar hydropathy profile, might be secreted and demonstrates that these hybrid proteins are secreted by the type III secretion system of Shigella flexneri2003Subtil Agathe; Parsot Claude; Dautry-Varsat AliceUS2004131624 (A1)
Bacterial system for protein transport in eukaryotic cellsDevelopment of a system for the targeted transport of proteins into eukaryotic cells by using a type III secretion system and bacteria strains that are mutated in hpaB or homogenous genes. The inventive bacterial system is used to transport bacterial proteins into eukaryotic cells, in order to influence or modify cellular processes such as gene expression, growth, development and defence/resistance mechanisms2005Bonas Ulla; Buettner DanielaWO2005085417 (A2)
Methods of identifying modulators of bacterial type III protein secretion systemProvides methods for identifying inhibitors or activators of bacterial type III protein secretion system by using a recombinant beta-lactamase that can be secreted by a type III protein secretion system. The assay could be easily adapted to a high throughput mode to allow daily screening of several tens of thousands compounds2005Goldschmidt Raul; Loeloff MichaelWO2005113791 (A2)
Pharmaceutical composition for the treatment of bacterial infections and sepsisThe invention involves a pharmaceutical composition comprising at least one glycogen synthase kinase 3 β; inhibitor, at least one Rho-kinase inhibitor, and an optional adequate pharmaceutical carrier for producing a drug for the preventive or therapeutic treatment of bacterial infectious diseases by synergistically increasing synthesis and secretion of type II. A secretory phospholipase A2 into the bloodstream so as to boost the body's inherent resistance to infections2005Menschikowski Mario; Hagelgans Albert; Siegert GabrieleWO2005120475
Pyridone compounds as inhibitors of bacterial type III protein secretion systemsProvides compounds that inhibit type III protein secretion useful for the treatment and prevention of bacterial infections, particularly those caused by Gram-negative bacteria, and methods for their use2005Li XiaobingUS2005256137 (A1)
Methods for stimulating an immune response using bacterial antigen delivery systemProvides methods for stimulating and/or increasing an immune response against tumor antigens through the use of the type III secretion system of bacteria. The invention also relates to the preparation of antigen presenting cells from peripheral blood mononuclear cells by using bacteria with a type III secretion system2006Old Lloyd J; Ritter Gerd; Nishikawa Hiroyoshi; Gnjatic Sacha; Galan Jorge EUS2009324651 (A1)
Screening system for inhibitors and activators of type III secretion machinery in Gram-negative bacteriaProvides a screening system (comprising inhibitors and activators of type III secretion machinery) that directly transfers pathogenic proteins of Gram-negative bacteria into a host cell to identify substances capable of activating or inhibiting the secretion of type III protein secretion system2006Hwang In Gyu; Moon Jae Sun; Kim Sung UkKR20080051240 (A)
Application of bovine lactoferrin for preparing a medicinal agent for inhibition of bacteria growthThe invention refers to a new application of bovine lactoferrin for preparing a medicinal agent for inhibiting bacteria growth. The bovine lactoferrin inhibits the growth of bacterial pathogens expressing the type III secretory system2007Makmakhon Robert Dzh; Kliari Tomas; Ochoa TerezaRU2007140789 (A)
Bacterial secretion system and uses-2007Gey Van Pittius Nicolaas Claudius; Warren Robin Mark; Van Helden Paul DavidZA200706520 (A)
Biopolymer and protein production using type III secretion systems of Gram-negative bacteriaProvides proteins, polynucleotide, expression cassette, vector and bacterium compositions for obtaining proteins of interest by expression of same in Gram-negative bacteria with a type III secretion system. Also provides uses for the proteins obtained in the manufacture of isolated proteins and pharmaceutical compositions2007Voigt Christopher Ashby; Widmaier Daniel MatthewWO2008019183 (A2)
Use of the Pseudomonas syringae effector protein HopU1 related to its ability to ADP-ribosylate eukaryotic RNA binding proteinsThe invention provides novel methods for modulation of the innate immune response of a plant to infection caused by Pseudomonas syringae, which injects effector proteins into host cells via a type III protein secretion system. Also provides methods for enhancing or suppressing the innate immune response of the plant2007Alfano James R; Fu Zheng Qing; Elthon Thomas EWO2008042026 (A2)
Method and means for preventing and inhibiting type III secretion in infections caused by Gram-negative bacteriaDiscloses a means of decreasing bacterial virulence in a mammal or in a plant by inhibition of the type III secretion system at concentrations that do not prevent or substantially reduce bacterial growth. Also disclosed are a therapeutic method and a pharmaceutical composition2008Elofsson MikaelUS2010099674 (A1)
Carboplatin compound inhibiting secretion system of phytopathogenic Gram-negative bacteria and biocontrol agent of plant diseases with this compoundProvides an agent for preventing plant diseases, containing carboplatin compounds, to selectively suppress secretion system related to plant pathogenicity2009-KR20110048335 (A)
Inhibition of quorum sensing-mediated processes in bacteriaProvides methods for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production2009Bassler Bonnie; Swem LeeUS2011123586 (A1)
Type III secretion inhibitors, analogs and uses thereofThe invention relates to compounds and compositions useful for inhibiting type III secretion systems in pathogenic bacteria, such as Yersinia pestis, and uses of such inhibitors in the treatment and prevention of disease2009Goguen Jon; Pan Ning; Lee KyungaeUS2011034463 (A1)
5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection1Provides a method for inhibiting Gram-negative bacterial pathogenesis, a method of screening for compounds that inhibit type III secretion in Gram-negative bacteria, and compounds that inhibit type III secretion in Gram-negative bacteria2010Felise Heather B; Miller Samuel I; Kline ToniUS2011039849 (A1)
Methods for Identifying Inhibitors of the type III Secretion System1Provides a method for determining whether a test compound can inhibit the function of the type III secretion system. The method identifies drug candidates that are highly specific anti-bacterial agents for treating diseases caused by Gram-negative bacteria with a T3SS2010Marlovits Thomas C; Radics Julia; Schmied WolfgangUS2013130283 (A1)
Attenuated Salmonella inducible secretory expression oral vaccine presentation system and application there of1The invention comprises an attenuated salmonella inducible secretory expression oral vaccine presentation system containing an antigen expression carrier. The system is controlled by a promoter induced by a microenvironment in an antigen presenting cell and excreted by induction of a bacteria excretion signal, and it uses the attenuated salmonella as the host of the antigen expression carrier2011Zichun Hua; Guo ChenCN102335421 (A)
Bacterial mediated delivery of nuclear protein into pluripotent and differentiated cells1A modified Pseudomonas aeruginosa type III secretion system has been developed that efficiently delivers selected proteins into a host cell2011Jin Shouguang; Bichsel CandaceWO2012012605 (A2)
Inhibitors of bacterial type III secretion system1Discloses organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems. These inhibitor compounds are useful for combating infections by Gram-negative bacteria with such type III secretion systems2012Moir Donald T.; Aiello Daniel; Peet Norton P; Williams John D; Torhan MatthewUS2014142134 (A1)
Table 3 Patents concerning the inhibition of quorum sensing systems
Patent titleDescriptionApplication dateInventorsPublication number
Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using themThis invention generally relates to novel compositions based on a structure designated as “Honaucin A”, including Honaucin A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them2011Gerwick William H; Gerwick Lena; Choi Huykjae; Villa Francisco A; Smith Jennifer; Rowley David CWO2011153502 (A2)
Composition for oral useA method for suppressing dental caries by regulating biofilm formation by the bacteria that cause dental caries instead of controlling these bacteria2011Tsugane Takanori; Saeki YojiEP2620160
Conjugates of acyl homoserine lactone and catalase a from Pseudomonas aeruginosaThe present invention relates to the acyl homoserine lactone N-3-(oxododecanoyl)-L-homoserine lactone or butyryl L-homoserine lactone and Pseudomona aeruginosa KatA protein, or an antigenic portion conjugate thereof, used to treat Pseudomona aeruginosa infections by limiting biofilm formation and inhibiting a range of quorum-sensing dependent virulence factors2011Kyd Jennelle M; Cooley MargaretWO/2012/083382
Enzyme bag containing quorum quenching enzyme immobilized silica for inhibiting biofilm formation and membrane bioreactor system for water treatment system using the bagThis invention relates to an enzyme bag containing silica-immobilized enzyme for inhibiting biofilm formation. A membrane bioreactor system for water treatment using the bag is provided for stable implementation of filtering operations over a long period of time by improving the performance of operational processes2011Lee Chung Hak; Yang Cheon Seok; Lee Jung Kee; Han Jong Yun; Lee Chung Hak; Yang Cheon Seoket; Lee Jung Kee; Han Jong YunKR20120134724 (A)
Fluidizable carrier with biofilm formation-inhibiting microorganisms immobilized therein and membrane water treatment apparatus using the sameThis invention relates to a biofilm formation-inhibiting microorganism immobilized fluidizable carrier in which a biofilm formation-inhibiting microorganism is fixed therein and a membrane water treatment apparatus including the same are provided to increase a membrane cleaning period2011Lee Chung Hak; Kim Sang Ryoung; Lee Jung KeeKR20130034935 (A)
Methods of disrupting quorum sensing to affect microbial population cell densityThe invention relates to the modulation of quorum sensing mechanisms in a microorganism for the purpose of exploiting the fermentation capabilities of the microorganism2011Marrs Barry; Swalla Brian MUS2011124522 (A1)
Quorum-sensing signal molecular preparation and application thereof in tobacco waste treatmentThe invention relates to the field of environmental biotechnology, in particular to preparation of a quorum sensing signal molecule and application in processing tobacco waste2011Meizhen Wang; Hongzhen He; Huajun Feng; Xin Zheng; Dongsheng Shen; Zhenmei LV; Hang MinCN102392051 (A)
Synthetic analogs of bacterial quorum sensorsThe invention relates to synthetic analogs of bacterial quorum sensing molecules, and methods of use of these2011Iyer Rashi; Ganguly Kumkum; Silks Louis AUS2012071430 (A1)
System and method for reversing the antibiotic tolerance of bacterial persister cellsThe present invention relates to antibiotics and, more particularly, to a system and method for decreasing the tolerance of bacterial persister cells to antibiotics2011Ren Dacheng; Pan JiachuanEP2603576
Triazole compounds as well as preparation method and application thereofThe present invention relates to triazole derivatives, the preparation method and as the autoinducer-2 (AI-2) quorum sensing inhibitors, belonging to anti-AI-2 quorum sensing type drug technology2011Minyong Li; Lvpei Du; Peng ZhuCN102219753 (A)
Use of a novel alpha-proteobacteria for quorum quenchingThe invention (concerning the fields of biology, molecular biology, and aquaculture) specifically relates to a new a-proteobacteria capable of degrading/V-acyl-homoserine lactones (AHLs) for control of bacterial infectious diseases and prevention of biofilm formation2011Otero Casal Ana María; Romero Bernardez ManuelWO2011154585 (A1)
2-methylthiopyrrolidines and their use for modulating bacterial quorum sensingFormula (I) compounds are disclosed and their use in inhibiting quorum sensing in bacteria is reported2012Malladi Venkata L; Schneper Lisa; Sobczak Adam J; Mathee Kalai; Wnuk Stanislaw FWO/2012/174511
Compositions for regulating or modulating quorum sensing in bacteria, methods of using the compounds, and methods of regulating or modulating quorum sensing in bacteriaThe report encompasses compounds and compositions that are useful as specific AI-2 antagonists for the control of bacterial quorum sensing and methods for inhibiting or attenuating microbial virulence, biofilm formation and drug resistance2012Wang Binghe; Ni Nantin; Wamg Junfeng; Lu Chung-Dar; Chou Han-Ting; Li Minyong; Zheng Shilong; Cheng Yunfeg; Peng HanjingEP2529793 (A2)
Construction and application of unmarked Lysobacter enzymogenes engineering strain capable of preventing plant bacteriosisThe invention (within the field of microbial genetic engineering), specifically relates to a plant bacterial disease that can prevent dissolving enzyme production strains of Bacillus unmarked engineering construction and application2012Liu Fengquan; Qian GuoliangCN102943061 (A)
Furan compound and preparation method and application of furan compoundThe invention relates to furan derivatives, the method of preparation and as the AI-2 quorum sensing inhibitors, are anti-AI-2 type of quorum sensing2012Minyong Li; Peng ZhuCN102603683 (A)
Method for increasing output of microbial lovastatin based on quorum sensing mechanismThe invention relates to the pharmaceutical raw material fermentation industry, in particular to a method of increasing microbial production of lovastatin2012Li HaomingCN102925509 (A)
Method for quickly identifying food-borne pathogen bacterial biofilm formation inhibitorThe invention relates to the field of food microbiology control technology, in particular to the rapid identification of an inhibitor of foodborne bacterial biofilm formation2012Wenyan Zhang; Hongmei Zhang; Zhihua Tao; Wenyuan ZhouCN102706821 (A)
Phosphorylated and branched dihydroxy-pentane-ione analogs as quorum sensing inhibitors in bacteriaThe invention provides compositions and methods for modulating quorum sensing in microbes and can be used in prophylactic methods or therapy for bacterial infections and for reduction of biofilms. The compounds are AI-2 analogs and as such have structures similar to 4,5-dihydroxy-2,3-pentanedione that can act as agonists/antagonists of quorum sensing2012Sintim Herman; Bentley William E; Roy Yarnika; Smith JacquelineUS2012294900 (A1)
Preparation method of imprinted polymer of bacterial quorum sensing signal molecule AI-1The present invention relates to bacterial quorum sensing signal molecules A1-1 imprinted polymer preparation2012Xin Li; Ling WangCN102604010 (A)
Probiotics for biological control against Vibrio sp.The invention relates to probiotics for biological control against Vibrio sp., and in particular, to a newly isolated bacillus strain that degrades quorum-sensing signal molecules of the pathogenic bacteria Vibrio sp., and inhibits biofilm formation2012Yang Si Yong; Woo Seo Hyung; Kang In Hye; Im Hyun JungWO2012105805
Quorum sensing inhibitor against a pathogenic microorganism, and an antibacterial composition using the sameA quorum sensing inhibitor and an antibacterial composition using the same are provided to suppress quorum sensing between bacteria, and to prevent or treat infection or diseases2012UndescribedKR101243696
Shewanella piezotolerans 34# and application thereof to algae inhibitionThe invention relates to the field of biotechnology, in particular to a marine bacterium Shewanella and the inhibition of algal growth2012Zhou Jin; Yin PengCN103173383 (A)
Simple method for testing disease resistance of pathogenic bacteria quorum-quenching gene prokaryotic expression productThe invention relates to a prokaryotic expression product of disease resistance testing methods, in particular to test pathogen populations prokaryotic expression product quenching effect of a simple disease, and belongs to the field of gene function identification techniques2012Ouyang Lejun; Huang Zhenchi; Zeng Fuhua; Li Limei; Li HengCN102972220 (A)
Use of quorum sensing inhibitors and biofilm dispersing agents for controlling biofilm-associated implantable medical device related infectionsThe invention generally relates to implantable medical devices and, more specifically, to the use of quorum sensing inhibitors and/or biofilm dispersing agents to control biofilm-associated infections related to the use of implantable medical devices2012Samade Richard; Dinesh Prashant; Nabutovsky Yelena; Bornzin Gene A; Poore John W; Karicherla Annapurna; Dalal NiravUS2014005605 (A1)
Bacillus pumillus microbial preparation with quorum sensing system inhibiting effectThe invention relates to Bacillus pumillus with a quorum sensing system inhibiting effect. The invention has the advantages that Chromobacterium violaceum is used for screening out a bacterial strain F3-1. It can be used to produce a microbial preparation capable of preventing and treating aquatic bacterial diseases2013Song Zengfu; Fan Bin; Chen BiaoCN103525723 (A)
Bicyclic furanones with low toxicity for microbial controlThe invention relates to a class of bicyclic brominated furanone structures with reduced toxicity and high activity for inhibiting biofilm formation and quorum sensing by microbes2013Luk Yan-Yeung; Yang SijieUS2013197077 (A1)
Method for detecting quorum sensing quenching bacterial strainThe invention relates to a method for detecting a quorum sensing quenching bacterial strain. The method comprises the addition of a bacterial strain to be detected in a PIPES (1,4-piperazinediethanesulfonic acid) buffer solution of pH 62013Zhang Xiaohua; Tang Kaihao; Shi Xiaochong; Zhang YunhuiCN103215342 (A)
Quorum-quenching enzyme OLB-26, and coding gene and application thereofThe invention relates to a quorum sensing quenching enzyme 0LB-26 and its coding gene and application2013Zhou Zhigang; Zhang Meichao; Yang Yalin; Xu Li; He Suxu; Li Qing; Yu QiangCN103275949 (A)
Targeted enzymatic degradation of quorum-sensing peptidesThe present invention generally relates to the fields of microbiology and wound care. More particularly, it concerns methods and compositions for inhibiting biofilms in wounds and on medical devices2013Alarcon Rodolfo; Mcnulty Amy KUS20130253382
Use of ellagitannins as inhibitors of bacterial quorum sensingMaterials and methods for the inhibition of bacterial QS are described. Methods of treating bacterial infections by administration of one or more ellagitannins in amounts effective for inhibiting bacterial QS are also provided2013Athee Kalai; Adonizio Allison L; Ausubel Frederick; Clardy Jon; Bennett Bradley; Downum KelseyUS2013317094 (A1)
Use of hydroxytirosol and derivatives thereof as quorum quenchersThe quorum quenching activity of formula (I) or (II) compounds, such as hydroxytyrosol (HT), hydroxytyrosol acetate (HTA), 3,4-dihydroxyphenylacetic acid (DOPAC) and derivatives thereof are described2013Au Ón Calles David; Allende Prieto Ana; Fábregas Casal Jaime; Gómez-Acebo Gullón EduardoWO2014060581 (A1)
Use of the cect 7426 strain for generating quorum quenching of the autoinducer-2 signal (ai-2)The invention relates to the use of a bacterial strain of the species Tenacibaculum discolor in the control of infectious diseases and for inhibiting biofilm formation caused by bacteria, through the inhibition of quorum sensing signals type AI -2. The invention applies to the field of molecular biology2013Otero Casal, Ana María; Romero Bernárdez ManuelWO2014057151 (A1)
Table 4 Patents concerning the inhibition of multidrug resistance systems
Patent titleDescriptionApplication dateInventorsPublication number
Method for screening for non-tetracycline efflux pump inhibitorsProvides screening methods for inhibitors of microbial efflux pumps and pharmaceutical compositions containing such efflux pump inhibitors as well as methods for treating microbial infections by use of these compositions1995Trias; Joaquim Chamberland; Suzanne Hecker; Scott J Lee; Ving JUS5989832 A
Efflux pump inhibitorsProvides screening methods for inhibitors of microbial efflux pumps and pharmaceutical compositions containing such efflux pump inhibitors. Also provides methods for treating microbial infections using those compositions1996Trias Joaquim; Hecker Scott J; Chamberland Suzanne; Lee Ving JCA2217865
Methods and compositions for reducing bacterial tolerance of disinfectants and organic solventsMethods and compositions useful for manipulating bacterial resistance to non-antibiotic antibacterial compositions, disinfectants and organic solvents, and for rendering bacterial cells susceptible to non-antibiotic antibacterial compositions1997Levy Stuart BWO9917607 (A2)
Methods and compositions for reducing bacterial tolerance to antibacterials, disinfectants and organic solventsMethods and compositions useful for manipulating bacterial resistance to non-antibiotic antibacterial compositions, disinfectants and organic solvents, and methods for rendering bacterial cells susceptible to non-antibiotic antibacterial compositions1997Levy Stuart BUS6068972 (A)
Inhibitors of cellular efflux pumps of microbesDescribes compounds that are inhibitors of efflux pump in bacteria. Also describes methods of preparing and using such compounds and the pharmaceutical compositions that include such compounds2001De Souza Noel John; Patel Mahesh Vithalbhai; Gupte Shrikant V; Upadhyay Dilip J; Shukla Milind Chintaman; Chaturvedi Nishith C; Bhawsar Satish B; Nair Sheela Chandresekharan; Jafri Mohammed A; Khorakiwala Habil FakhruddinUS2002177559 (A1)
Drug discovery and increased potency of antiseptics and disinfectants based on high extracellular pH, the disablement of cellular efflux pumps, and the unexpected synergism therebetweenMethods for increasing the therapeutic potency of amphipathic compounds, e.g., antiseptics and disinfectants, and the exploitation of these discoveries in the screening of small molecules, and libraries thereof, for biological activity in prokaryotes and eukaryotes2002Lewis Kim; Hsieh PeichungUS2003118541 (A1)
Methods to study and mechanisms of biofilm-related antibiotic resistanceDiscloses various genes that encode proteins shown to play a role in microbial resistance of an organism in a biofilm and homologs thereof. Describes methods of identifying a compound that modulates microbial resistance of an organism in a biofilm and also genes encoding proteins that play a role in biofilm resistance2002O'Toole George A; Mah Thien-FahUS2003166030 (A1)
Minicell-based gene therapyProvides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery2002Sabbadini Roger A; Berkley Neil; Surber Mark WUS2003199088 (A1)
Potentiators of antibacterial activityThe invention relates to compounds that potentiate the activity of antibacterials, compositions useful in treating bacterial infection, and related methods. Also relates to a method of inhibiting bacterial efflux of an antibiotic, thereby increasing its efficacy2004Grossman Trudy HUS20040887719 20040709
Substituted polyamines as inhibitors of bacterial efflux pumpsMethods of treating bacterial infections, including those caused by multidrug resistant bacteria, by using polyamine efflux pump inhibiting compounds, optionally in combination with other drugs such as antibiotics. The pharmaceutical compositions of the polyamines are also reported2004Nelson Mark L; Alekshun Michael NUS2004204378 (A1)
Essential and important genes of Pseudomonas aeruginosa and the use thereof to design or identify antibacterial agentsDatabase of candidate essential genes in Pseudomonas aeruginosa, and other important genes that, when mutated, produce a growth attenuated phenotype. The invention includes methods for confirming the need for or importance of candidate genes, methods for using those genes to screen for new antibacterial drugs, the antibacterial agents identified using the disclosed methods, and also methods of using the same for treating and preventing Pseudomonas infection2005Bruce Kim F; Warrener Paul; Hou KevinUS2007196829 (A1)
Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitorsProvides methods and compositions for increasing the susceptibility of PDF inhibitors against Gram-negative organisms by using efflux pump inhibitors2005Dean Charles Richard; Ryder Neil StewartCA2569681
Products and methods for in vivo secretion of monatinProvides products and methods for the in vivo production of monatin sweetener. The products include microorganisms that are genetically modified to secrete or to improve secretion of monatin, to produce monatin, and to both secrete/ improve secretion and produce monatin2006Laplaza Jose; Anderson James C; Desouza Mervyn L; Hicks Paula M; Kollmann Sherry RWO2006113897
Rhamnose-inducible expression systems and methodsDescribes rhamnose-inducible expression constructs which may include at least one rhamnose-inducible regulatory element expressing a regulatory protein and one promoter that is inducible by the regulatory protein. An open reading frame expressing a protein of interest may be placed under control of the promoter. Also describes optimized Shine-Dalgarno sequences for use with the promoter2006Surber Mark WUS2007122881 (A1)
Enhancement of tigecycline potency using efflux pump inhibitorsDiscloses Efflux Pump Inhibitor (EPI) compounds that can be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens and methods of treatment and pharmaceutical compositions for co-administering tigecylcine with an EPI2007Glinka Tomasz; Bostian Keith; Lomovskaya Olga; Surber Mark; Sun DongxuUS20070832626 20070801
Method or agent for inhibiting the function of efflux pump of Pseudomonas aeruginosaDiscloses a method comprised of modifying any amino acid residue selected from 100th to 109th and 311th to 320th amino acid residues in an amino acid sequence for mature OprM protein, as well as an agent for inhibiting the function of an efflux pump of Pseudomonas aeruginosa with good efficiency. Further disclosed is a method for screening the agent2007Yoshihara Eisaku; Inoko HidatoshiCA2641988
Method or agent for inhibiting the function of efflux pump of Pseudomonas aeruginosaProvides a method for inhibiting the function of the drug efflux pump of Pseudomonas aeruginosa, comprising modification of any amino acid residue selected from 100th to 109th or 311th to 320th amino acid residues in the amino acid sequence of mature OprM protein. Also reports an agent with such inhibitory effect, as well as a screening method2007Yoshihara Eisaku; Inoko HidatoshiWO2007/091395
Microbial production of aromatic acidsMethod for the microbial production of aromatic acids from a fermentable carbon substrate using a host cell capable of producing said aromatic acid, and comprising an efflux pump for said aromatic acid. A preferred host cell comprises a member of the proton-dependent resistance/nodulation/cell division (RND) family of efflux pumps2007Wery JanUS2007259409 (A1)
Near-infrared electromagnetic modification of cellular steady-state membrane potentialsDiscloses systems and methods for applying near-infrared optical energies and dosimetries to alter the bioenergetic steady-state trans-membrane and mitochondrial potentials (DeltaPsi-steady) of all irradiated cells through an optical depolarization effect. This membrane depolarization provides the ability to potentiate antimicrobial, antifungal and/or antineoplastic drugs against only targeted undesirable cells2007Bornstein EricUS2008139992
In vivo gene sensorsDescribes methods and compositions for the detection of target genes that permit the selective expression of an effector gene in those cells expressing the target gene, thus selectively targeting these cells for treatment or elimination. The methods and compositions described may also permit the selective expression of an agent such as a therapeutic gene product, in a targeted population of cells2009Collins James J; Lu Timothy Kuan-TaWO2009/137136
Methods of reducing microbial resistance to drugsProvides methods of treating infection, screening for inhibitors of AcrAB-like efflux pumps, and enhancing antimicrobial activity of drugs. Pharmaceutical composition comprising an inhibitor of an AcrAB-like efflux pump and an antimicrobial agent are also provided2009Oethinger Margaret; Levy Stuart BUS2009298873
Minicells displaying antibodies or derivatives thereof and comprising biologically active compounds1Minicells are used to deliver biologically active compounds, including polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell2011Sabbadini Roger A; Berkley Neil; Surber Mark W; Klepper RobertUS20070725196 20070316